Electrochemotherapy for Breast Cancer—Results From the INSPECT Database

Neoadjuvant treatment by ECT in cutaneous malignant neoplastic lesions

“…7 , 8 Several studies have shown and confirmed ECT efficacy and safety in the treatment of cutaneous and subcutaneous lesions from any histological origin. [9][10][11] Recently, new indications have been explored for the treatment of internal organs such as the bone, the liver, the pancreas [12][13][14][15] and specific indications such as vulvar cancer, soft tissue sarcoma and Kaposi sarcoma [16][17][18][19] have been studied in depth. Considering the current evidence, the authors of this study have hypothesised the potential role of ECT as a neoadjuvant treatment of cutaneous or subcutaneous neoplastic lesions.…”

Electrochemotherapy in the Treatment of Breast Cancer Metastasis to the Skin and Subcutaneous Tissue - Multicenter Experience

“…Among the patients included in that study 14 were diagnosed with breast cancer, and in this subgroup a 95% OR was obtained. Since then, numerous scientific studies have proved the effectiveness of this method in the treatment of cutaneous metastasis, regardless of histology, with effectiveness in the form of a positive response to treatment ranging from 16% to 100% (with an average of > 70%) [9,10,11,12,13]. Updated standard operating procedures for ECT were published in 2018.…”

Electrochemotherapy of superficial tumors – Current status:

“…Overall, 1-year local progression-free survival (LPFS) was 86.2%. Comparable results were observed in 90 patients from the International network for sharing practices of ECT database [162] . A prospective registry has been activated (ISRCTN study ID: ISRCTN56719146) aiming to identify reliable patient selection criteria.…”

“…The published experiences indicates it is possible to achieve high response rates and prolonged local control with ECT ( Table 5 ) [ 11,115,116,119,142,[159][160][161][162] , and tumor size represents the most reliable predictive parameter [142,160,161,163] . Waiting for future studies, actionable recommendations include the following: the procedure is tolerable by elderly patients [119] ; the chance to obtain an effective chest wall control inversely correlates with the scattering of skin metastases [115] ; ECT is active in previously irradiated fields, although retreatment may be associated with increased pain and skin toxicity [115] ; in this setting, BLM should be used with caution given its known ability to induce radiation recall toxicity, even though this has not emerged as a problem at present.…”